The challenge of developmental therapeutics for adrenocortical carcinoma

@inproceedings{Costa2016TheCO,
  title={The challenge of developmental therapeutics for adrenocortical carcinoma},
  author={Ricardo L B Costa and Benedito A. Carneiro and Fabio A. Tavora and Sachin Gopalkrishna Pai and Jason Benjamin Kaplan and Young Kwang Chae and Sunandana Chandra and Peter Andreas Kopp and Francis J Giles},
  booktitle={Oncotarget},
  year={2016}
}
Adrenocortical carcinoma (ACC) is a rare disease with an estimated incidence of only 0.7 new cases per million per year. Approximately 30-70% of the patients present with advanced disease with very poor prognosis and without effective therapeutic options. In the recent years, unprecedented progresses in cancer biology and genomics have fostered the development of numerous targeted therapies for various malignancies. Immunotherapy has also transformed the treatment landscape of malignancies such… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS